Tremendous advances have been made in the treatment of NSCLC that is positive for epidermal growth factor receptor (EGFR) mutations.1From 2003-2016, nearly half of the new medications approved for the treatment of lung cancer addressed this particular molecular profile.1
Despite this progress, there is still a need for investigational medications that aim to target EGFR mutations, as some lung cancers with EGFR mutations don’t respond to current targeted medications, and those that do almost always become resistant over time.
The following research studies are currently evaluating the safety and efficacy
of investigational medicines for the treatment of NSCLC in patients with EGFR.
NGS is a DNA sequencing technology method that can detect abnormalities across the entire genome, including substitutions, deletions and insertions. Using NGS, multiple genes can be tested for mutations simultaneously, often in less time and at less cost than standard sequencing approaches.2
If you have an EGFR-positive patient that may be a candidate for one of these clinical research studies, or would like to share this information with a colleague, you can do any of the following:
Share this website to provide education and awareness about these investigational research studies. Patients can also take a simple questionnaire to see if they may be eligible.
Encourage your patient to contact our nurses to ask any questions they may have and see if they may be eligible to participate in a study.
Visit Global Trial Finder to locate Janssen clinical research studies that may be looking for participants all around the world.